Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Accenture
Johnson and Johnson
Healthtrust
Teva
US Army
Chinese Patent Office
Fuji
Citi

Generated: December 15, 2018

DrugPatentWatch Database Preview

SYNAGIS Drug Profile

« Back to Dashboard

Summary for Tradename: SYNAGIS
Pharmacology for SYNAGIS
Ingredient-typeAntibodies, Monoclonal
Mechanism of ActionFusion Protein Inhibitors

US Patents for SYNAGIS

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Medimmune SYNAGIS palivizumab VIAL 103770 002 1998-06-19 ➤ Try a Free Trial LegoChem Biosciences, Inc. (Daejeon, KR) ➤ Try a Free Trial RX search
Medimmune SYNAGIS palivizumab VIAL 103770 002 1998-06-19 ➤ Try a Free Trial Janssen Vaccines & Prevention B.V. (Leiden, NL) ➤ Try a Free Trial RX search
Medimmune SYNAGIS palivizumab VIAL 103770 002 1998-06-19 ➤ Try a Free Trial ATOPIX THERAPEUTICS LIMITED (London, GB) ➤ Try a Free Trial RX search
Medimmune SYNAGIS palivizumab VIAL 103770 002 1998-06-19 ➤ Try a Free Trial GILEAD SCIENCES, INC. (Foster City, CA) ➤ Try a Free Trial RX search
Medimmune SYNAGIS palivizumab VIAL 103770 002 1998-06-19 ➤ Try a Free Trial Alios BioPharma, Inc. (South San Francisco, CA) ➤ Try a Free Trial RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for SYNAGIS

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015000061 Germany ➤ Try a Free Trial PRODUCT NAME: TRASTUZUMAB UND RECOMBINANTE HUMANE HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
2016 00031 Denmark ➤ Try a Free Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326
2015031 Lithuania ➤ Try a Free Trial PRODUCT NAME: TRASTUZUMABAS IR REKOMBINANTINE ZMOGAUS HIALURONIDAZE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
2016000049 Germany ➤ Try a Free Trial PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
0822 Netherlands ➤ Try a Free Trial PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 - UITVOERINGSBESLUIT C(2014)2048 20140326
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Fuji
Cantor Fitzgerald
Baxter
Chubb
Farmers Insurance
Teva
Citi
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.